V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Trials Network.

Sera from 11 volunteers immunized with a recombinant HIV-1 gp160-expressing vaccinia virus (HIVAC-1e; Oncogen/Bristol-Myers Squibb, Seattle, WA) and boosted with baculovirus-derived rgp160 (VaxSyn; MicroGeneSys, Inc., Meriden, CT) were evaluated for functional serum antibodies and their epitopes. Se...

תיאור מלא

מידע ביבליוגרפי

הוצא לאור ב:	J Clin Invest
Principais autores:	Montefiori, D C, Graham, B S, Zhou, J, Bucco, R A, Schwartz, D H, Cavacini, L A, Posner, M R
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	American Society for Clinical Investigation 1993
נושאים:	Research Article
גישה מקוונת:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC294922/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/8349820/ https://ncbi.nlm.nih.govhttps://doi.org/10.1172/JCI116658
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!